SkinBiotherapeutics plc (SkinBio) is a UK-based life sciences company focused on skin health through microbiome science. A spin-out from the University of Manchester, the company develops biologically derived actives and formulations intended for use in skincare, dermatology, and consumer health. SkinBiotherapeutics is listed on London’s AIM market.
The company’s research centres on bacterial lysates and related bioactives that can influence skin barrier function, the skin’s microbiota balance, and inflammatory responses. Applications span cosmetic ingredients for personal care as well as investigational approaches to dermatological conditions. SkinBiotherapeutics advances its pipeline through laboratory and early clinical studies and pursues a partnering model for scale-up and market access, while also supporting direct-to-consumer offerings in the gut–skin axis space via its AxisBiotix brand. The business operates through collaborations with academic groups and industry partners, with manufacturing typically executed by specialist suppliers.
